Patient-Reported Symptoms and Quality of Life During Treatment With Tamoxifen or Raloxifene for Breast Cancer Prevention
Open Access
- 21 June 2006
- journal article
- research article
- Published by American Medical Association (AMA) in JAMA
- Vol. 295 (23) , 2742-2751
- https://doi.org/10.1001/jama.295.23.joc60075
Abstract
The National Surgical Adjuvant Breast and Bowel Project (NSABP) Study of Tamoxifen and Raloxifene (STAR) was a multicenter, double-blind, randomized phase 3 prevention trial designed to evaluate the relative efficacy of raloxifene (60 mg/d for 5 years) compared with tamoxifen (20 mg/d for 5 years) in reducing the incidence of invasive breast cancer in high-risk postmenopausal women. In addition, it was hypothesized that raloxifene would have a better safety profile with respect to uterine cancer and a number of patient-reported symptoms and would provide a potential alternative to tamoxifen in the prevention of breast cancer in postmenopausal women. Therefore, measurement of patient-reported outcomes was an important secondary objective of the STAR trial.Keywords
This publication has 17 references indexed in Scilit:
- Functional Impact of Breast Cancer by Age at DiagnosisJournal of Clinical Oncology, 2004
- Effects of Estrogen plus Progestin on Health-Related Quality of LifeNew England Journal of Medicine, 2003
- Methodological Issues in the Analysis of Quality of Life Data in Clinical Trials: Illustrations from the National Surgical Adjuvant Breast and Bowel Project (NSABP) Breast Cancer Prevention TrialPublished by Springer Nature ,2002
- Validating and Improving Models for Projecting the Absolute Risk of Breast CancerJNCI Journal of the National Cancer Institute, 2001
- Health-Related Quality of Life and Tamoxifen in Breast Cancer Prevention: A Report From the National Surgical Adjuvant Breast and Bowel Project P-1 StudyJournal of Clinical Oncology, 1999
- Reduction of Vertebral Fracture Risk in Postmenopausal Women With Osteoporosis Treated With RaloxifeneResults From a 3-Year Randomized Clinical TrialJAMA, 1999
- Tamoxifen for Prevention of Breast Cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 StudyJNCI Journal of the National Cancer Institute, 1998
- Base-Line Quality-of-Life Assessment in the National Surgical Adjuvant Breast and Bowel Project Breast Cancer Prevention TrialJNCI Journal of the National Cancer Institute, 1995
- Projecting Individualized Probabilities of Developing Breast Cancer for White Females Who Are Being Examined AnnuallyJNCI Journal of the National Cancer Institute, 1989
- The Center for Epidemiologic Studies Depression Scale: its use in a community sampleAmerican Journal of Psychiatry, 1983